U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. SPY
4. ABBV
5. META
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Gilead Sciences (NASDAQ: GILD) Delayed: 125.05 --0 (-0%)
Previous Close $125.05    52 Week High $108.63 
Open $125.05    52 Week Low $71.39 
Day High $125.05    P/E 69.09 
Day Low $125.05    EPS $1.81 
Volume 1,577